Back to results
US 6,586,463 B2Granted
C16 unsaturated FP-selective prostaglandins analogs
AssigneeThe Procter & Gamble Company
InventorsMitchell Anthony deLong, David Lindsey Soper, John August Wos, Biswanath De
Life of this patent
Estimating the term…
Abstract
Compounds having the general structure: which are useful for the treatment of a variety of diseases and conditions, such as bone disorders.
Claims18
A compound having the structure:
- wherein
- a) R1 is selected from the group consisting of CO2H, C(O)NHOH, C2R3,CH2OH, S(O)2R3, C(O)NHR3. C(O)NHS(O)2R4, and tetrazole, wherein R3 is alkyl, heteroalkyl, carbocyclic aliphatic ring, heterocyclic alphatic ring, monocyclic aromatic ring, or monocyclic heteroaromatic ring;
- and
- R4 is alkyl, heteroalkyl, carbocyclic aliphatic ring, heterocyclic aliphatic ring, monocyclic aromatic ring, or monocyclic heteroaromatic ring;
- (b) R2 is H or lower alkyl;
- (c) X is a covalent bond;
- (d) Z is an aromatic ring or a heteroaromatic ring provided that when Z is a heteroaromatic ring and X is a covalent bond, Z is attached to C15 via a Carbon member atom;
- and
- (e) any optical isomer, diastereomer enantiomer of the above structure or a pharmaceutically-acceptable salt, or bio-hydrolyzable amide, ester, or imide thereof.
6 more elements
A method of treating a human or other animal subject having a bone disorder, said method comprising administering to said subject a compound according to the structure:
- wherein
- (a) R1 is selected from the group consisting of CO2H, C(O)NHOH, CO2R3, CH2OH, S(O)2R3, C(O)NHR3, C(O)NHS(O)3R4, and tetrazole;
- wherein R1 is alkyl, heteroalkyl, carbocyclic aliphatic ring, heterocyclic aliphatic ring, monocyclic aromatic ring, or monocyclic heteroaromatic ring;
- and
- R4 is alkyl, heteroalkyl, carbocyclic aliphatic ring, heterocyclic aliphatic ring, monocyclic aromatic ring, or monocyclic heteroaromatic ring;
- (b) R3 is H or lower alkyl;
- (c) X is a covalent bond;
- (d) Z is an aromatic ring or a heteroaromatic ring provided that when Z is a heteroaromatic ring and X is a covalent bond, Z is attached to C15 via a Carbon member atom;
- and
- (e) any optical isomer, diastereomer, enantiomer of the above structure or a pharmaceutically-acceptable salt, or bio-hydrolyzable, amide, ester, or imide thereof.
7 more elements
A method of treating glaucoma, said method comprising administering to human or other animal a safe and effective amount of a compound according to the structure:
- wherein
- (a) R1 is selected from the group consisting of CO3H, C(O)NHOH, CO2R3, CH2OH, S(O)2R3, C(O)NHR3, C(O)NHS(O)2R4, and tetrazole;
- wherein R1 is alkyl, heteroalkyl, carbocyclic aliphatic ring, heterocyclic aliphatic ring, monocyclic aromatic ring, or monocyclic heteroaromatic ring;
- and R4 is alkyl, heteroalkyl, carbocyclic aliphatic ring, heterocyclic aliphatic ring, monocyclic aromatic ring, or monocyclic heteroaromatic ring;
- (b) R2 is H or lower alkyl;
- (c) X is a covalent bond;
- (d) Z is an aromatic ring or a heteroaromatic ring provided that when Z is a heteroaromatic ring and X is a covalent bond, Z is attached to C15 via a Carbon member atom;
- and
- (e) any optical isomer, diastereomer, enantiomer of the above structure or a pharmaceutically-acceptable salt, or bio-hydrolyzable, amide, ester, or imide thereof.
6 more elements
Dependencies are inferred from the claim text.